shutterstock_1140355787_piotr_swat

Piotr Swat / Shutterstock.com

1 March 2019Americas

US FTC settles pay-for-delay case with AbbVie

The US Federal Trade Commission (FTC) concluded a ten-year pay-for-delay suit yesterday, with AbbVie agreeing not to enter certain settlements in patent cases that delay market entry of generic drugs.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Seventh Circuit urged to review AbbVie antitrust ruling

15 October 2020 Twenty US states, the US Federal Trade Commission, and consumer groups have asked the Seventh Circuit of the US Court of Appeals to reconsider a case claiming that AbbVie strived to prevent competition to its immunosuppressant drug, Humira.

Pay-for-delay settlements fall for second year: FTC report

6 November 2017 Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.

FTC welcomes Supreme Court 'pay-for-delay' ruling

25 July 2013 The chair of the FTC has said it will continue to challenge pay-for-delay court settlements in the pharmaceutical industry and has hailed a Supreme Court ruling as a victory for consumers.

More on this story

Seventh Circuit urged to review AbbVie antitrust ruling

15 October 2020 Twenty US states, the US Federal Trade Commission, and consumer groups have asked the Seventh Circuit of the US Court of Appeals to reconsider a case claiming that AbbVie strived to prevent competition to its immunosuppressant drug, Humira.

Pay-for-delay settlements fall for second year: FTC report

6 November 2017 Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.

FTC welcomes Supreme Court 'pay-for-delay' ruling

25 July 2013 The chair of the FTC has said it will continue to challenge pay-for-delay court settlements in the pharmaceutical industry and has hailed a Supreme Court ruling as a victory for consumers.

More on this story

Seventh Circuit urged to review AbbVie antitrust ruling

15 October 2020 Twenty US states, the US Federal Trade Commission, and consumer groups have asked the Seventh Circuit of the US Court of Appeals to reconsider a case claiming that AbbVie strived to prevent competition to its immunosuppressant drug, Humira.

Pay-for-delay settlements fall for second year: FTC report

6 November 2017 Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.

FTC welcomes Supreme Court 'pay-for-delay' ruling

25 July 2013 The chair of the FTC has said it will continue to challenge pay-for-delay court settlements in the pharmaceutical industry and has hailed a Supreme Court ruling as a victory for consumers.

More features

Could Apple v Masimo limit patent cases at the ITC?

Eli Lilly strikes again in weight-loss drugs fight

Novartis moves to block cancer drug generic in US

WATCH: China patent landscape—AI, patent linkage, export controls, and more

China bars USPTO employee from leaving country

UPC hands rare default win to Insulet, bans insulin pump in EU

GSK loses appeal over purple inhaler TM in Europe

Astellas defends Xtandi patent as court rejects generics’ appeal